A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum

被引：0
|
作者：
Park, S.
Lee, S.
Kang, J.
Hwang, I.
Lee, J.
Park, J.
Park, Y.
Lim, H.
Kang, W.
机构：
[1] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea
[2] Dankook Univ Hosp, Cheonan, South Korea
[3] Gyeongsang Natl Univ Hosp, Jinju, South Korea
[4] Chung Ang Univ, Yong San Hosp, Seoul 156756, South Korea
[5] Soon Chun Hyang Univ Hosp, Seoul, South Korea
[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med, Seoul, South Korea
[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.4147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4147
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
    Satoh, Taroh
    Lee, Kyung Hee
    Rha, Sun Young
    Sasaki, Yasutsuna
    Park, Se Hoon
    Komatsu, Yoshito
    Yasui, Hirofumi
    Kim, Tae-You
    Yamaguchi, Kensei
    Fuse, Nozomu
    Yamada, Yasuhide
    Ura, Takashi
    Kim, Si-Young
    Munakata, Masaki
    Saitoh, Soh
    Nishio, Kazuto
    Morita, Satoshi
    Yamamoto, Eriko
    Zhang, Qingwei
    Kim, Jung-mi
    Kim, Yeul Hong
    Sakata, Yuh
    GASTRIC CANCER, 2015, 18 (04) : 824 - 832
  • [22] Second-Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First-Line Trial
    Ramaswamy, Anant
    Patil, Vijay
    Joshi, Amit
    Noronha, Vanita
    Chougule, Anuradha
    Mahajan, Abhishek
    Goud, Supriya
    More, Sucheta
    Karpe, Ashay
    Pande, Nikhil
    Chandrasekharan, Arun
    Goel, Alok
    Talreja, Vikas
    Prabhash, Kumar
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1225 - S1225
  • [23] Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial
    Dongiovanni, V
    Buffoni, L
    Berruti, A
    Dongiovanni, D
    Grillo, R
    Barone, C
    Addeo, A
    Camilla, F
    Bertetto, O
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (02) : 203 - 209
  • [24] Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial
    Vincenzo Dongiovanni
    Lucio Buffoni
    Alfredo Berruti
    Diego Dongiovanni
    Raffaella Grillo
    Carla Barone
    Alfredo Addeo
    Camilla Fissore
    Oscar Bertetto
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 203 - 209
  • [25] CORRELATION BETWEEN THE EFFECTS OF FIRST-LINE CHEMOTHERAPY AND SURVIVAL TIME FROM SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Tabuse, H.
    Yasui, H.
    Funakoshi, T.
    Hamauchi, S.
    Tsushima, T.
    Taniguchi, H.
    Todaka, A.
    Yokota, T.
    Machida, N.
    Yamasaki, K.
    Fukutomi, A.
    Onozawa, Y.
    Boku, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99
  • [26] Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design
    Markman, M
    Markman, J
    Webster, K
    Zanotti, K
    Kulp, B
    Peterson, G
    Belinson, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3120 - 3125
  • [27] Umbrella strategy with systemic and intraperitoneal chemotherapy versus systemic chemotherapy in patients with advanced gastric cancer: a multicenter, randomized Phase III clinical trial
    Yang Yang
    Jia Wei
    Juan Du
    Zhengyun Zou
    Rongfu Wei
    Fenglin Zhang
    Weisheng Shen
    Xiyan Lu
    Sanyuan Sun
    Xiaoqin Li
    Chunlan Nie
    Gang Chen
    Lixia Yu
    Hanqing Qian
    Yan Yang
    Qin Liu
    Jie Shen
    Lifeng Wang
    Yajun Xing
    Fangbo Cui
    Jianmin Shi
    Lei Xi
    Lichun Deng
    Xiangmin Cao
    Qing Zhu
    Yuan Yuan
    Meilian Cheng
    Hui Xu
    Ling Yuan
    Miaomiao Guo
    Meng Wang
    Changyan Gao
    Xiaoping Qian
    Wenxian Guan
    Baorui Liu
    Clinical Cancer Bulletin, 2 (1):
  • [28] Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
    Weiss, Glen J.
    Langer, Corey
    Rosell, Rafael
    Hanna, Nasser
    Shepherd, Frances
    Einhorn, Lawrence H.
    Nguyen, Binh
    Paul, Sofia
    McAndrews, Patrick
    Bunn, Paul A., Jr.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4405 - 4411
  • [29] Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer
    Fushida, Sachio
    Kaji, Masahide
    Oyama, Katsunobu
    Hirono, Yasuo
    Nezuka, Hideaki
    Takeda, Toshiya
    Tsukada, Tomoya
    Fujimoto, Daisuke
    Ohyama, Shigekazu
    Fujimura, Takashi
    Ohta, Tetsuo
    ONCOTARGETS AND THERAPY, 2015, 8 : 939 - 941
  • [30] Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Doi, Toshihiko
    Ohtsu, Atsushi
    GASTRIC CANCER, 2014, 17 (02) : 362 - 370
12345